Abstract:

Objective To study the improvement of tumor marker levels in patients with breast cancer treated with docetaxel combined with pirarubicin chemotherapy. Method A total of 72 breast cancer patients who were treated in Liangshan County People's Hospital in Jining City from January 2019 to December 2019 were included in this study. They were divided into groups according to the coin toss method. The control group (typeface)of 36 patients received paclitaxel combined with pirarubicin. 36 cases in the observation group (flower face) were treated with docetaxel combined with pirarubicin. The tumor marker levels, toxic and side effects, disease control, 1-year survival rate and recurrence rate were compared between the two groups. Result After chemotherapy, the levels of CEA, CA125, CA153 and the 1-year recurrence rate in the observation group were lower than those in the control group, and the disease control rate was higher than that in the control group, and the difference was statistically

significant (P ＜ 0.05). There was no significant difference between the incidence rate and the 1-year survival rate (P ＞ 0.05). Conclusion Cetaxel combined with pirarubicin chemotherapy for breast cancer patients has an ideal effect, which can improve the level of tumor markers, and does not increase the incidence of adverse drug reactions and recurrence.

Key words: Breast cancer, Docetaxel, Pirarubicin, Chemotherapy, Tumor markers